Egypt, Australia explore expanding healthcare cooperation, green transformation initiatives
El-Sobky noted that discussions included the launch of a proposed twinning programme between Sydney Children's Hospital and Ramsey Health Care Group in Australia, and El-Nasr Specialized Children's Hospital in Port Said, as well as other pediatric units within the EHA network. The initiative aims to advance pediatric care services in Egypt by fostering knowledge transfer, joint training programmes, and the adoption of global best practices in subspecialties.
During the meeting, El-Sobky also presented the EHA's strategy for sustainability and green transformation. He highlighted the achievements of Sharm El-Sheikh International Hospital and Port Said Specialized Ophthalmology Hospital, which have both received international recognition from the Global Green and Healthy Hospitals (GGHH) network. These accolades underscore Egypt's commitment to embedding environmental sustainability into its healthcare system.
El-Sobky expressed the authority's keen interest in collaborating with Australia on sustainable healthcare initiatives, emphasizing the importance of sharing expertise to support the EHA's green strategy. This direction aligns with Egypt's broader national efforts toward sustainable development and the global shift toward environmentally conscious health systems.
The meeting also covered several proposed areas of cooperation, including medical tourism, joint research on clinical care quality indicators, advanced training programmes for healthcare providers, and exchange visits for medical delegations to Australia. These initiatives are designed to enhance healthcare delivery, boost the performance of medical teams, and further position Egypt as a regional hub for quality healthcare services.
El-Sobky underscored Egypt's potential as a promising market for healthcare investment and extended an invitation to Ambassador Wabenhorst to visit the Suez Medical Complex—one of the flagship facilities of the EHA in the Canal Governorates.
For his part, Ambassador Wabenhorst praised Egypt's significant strides in healthcare, describing them as a 'qualitative leap.' He expressed enthusiasm for deepening collaboration and reaffirmed Australia's commitment to supporting ongoing and future health partnerships with Egypt.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
2 days ago
- Zawya
Egypt: State-owned Holdipharma targets $371mln in revenues for FY2025/2026
Egypt - Mohamed El-Shimy, Minister of Public Enterprises, affirmed that the pharmaceutical industry is a vital pillar of health security and a key driver of the national economy, stressing that its development within the ministry's affiliated companies is a strategic priority. His remarks came while chairing the General Assembly meeting of the Holding Company for Pharmaceuticals (Holdipharma) to approve the budget plan for the 2025/2026 fiscal year. During the meeting, Ashraf El-Khouly, CEO and Managing Director of Holdipharma, presented the board's report, which included the draft budget for the coming fiscal year. The plan targets consolidated revenues of EGP 18bn, a 131% increase compared to 2023/2024, and net profits of EGP 3.4bn—up 343%. The report also noted the growth in the market value of the group's listed companies. The meeting, attended by Board Chair Ahmed Hegazy, members of the General Assembly, and representatives of the Central Auditing Organisation, marked the final approval of all holding companies' and subsidiaries' budgets for the new fiscal year. Minister El-Shimy explained that the ministry is working to localise and deepen pharmaceutical manufacturing, transfer and apply the latest global production technologies, and enhance product quality to strengthen competitiveness in local, regional, and international markets. Development plans include upgrading production lines, increasing manufacturing capacity, adhering to the highest standards of sustainability, quality, and Good Manufacturing Practice (GMP), ensuring occupational health and safety, and optimising the use of assets, capacities, and resources. He added that human capital development is central to achieving these targets, through specialised training and qualification programmes that encourage innovation and advance scientific research, alongside fostering partnerships with the private sector both domestically and internationally. These measures aim to increase production and export capacity, and open new markets to bolster the competitiveness of the national industry. El-Shimy stressed that reforming the financial structures of subsidiary companies is a top priority to ensure sustainable profitability and secure the resources needed for production expansion. He underscored the importance of updating organisational structures and management systems to meet current needs, while accelerating the implementation of the Enterprise Resource Planning (ERP) system to improve operational efficiency and ensure precise oversight of resources and production. The presentation also highlighted major projects and investment opportunities, including the production of biological drugs, insulin and biosimilars, dry powder inhalation tablets, active pharmaceutical ingredients (APIs), and hormones. It outlined partnerships with leading international companies, such as US-based Dawah, to produce and export products including ampoules, nutritional supplements, sterile injections, and sterile ophthalmic preparations. El-Shimy concluded by stressing the integration of economic, social, and environmental dimensions to ensure comprehensive sustainability in the company's activities. He called for promoting professional conduct, improving the work environment, and raising performance standards across all administrative and executive levels. He affirmed that the Ministry of Public Enterprises Sector is moving decisively towards modernising and restructuring its subsidiaries, striking a balance between profitability and sustainability, and enhancing Egypt's competitiveness regionally and globally. Holdipharma, he added, aims to achieve regional leadership in the sector, positioning Egypt as an advanced hub for pharmaceutical production and exports, meeting domestic needs while expanding into international markets. © 2025 Daily News Egypt. Provided by SyndiGate Media Inc. (
Gulf Today
4 days ago
- Gulf Today
Insane tariff
The American medical system has faced many criticisms, mostly valid, especially in terms of cost and availability. Just when you think it couldn't get worse, it does. One disaster is the recent cuts, by Robert Kennedy Jr, of $US500 million in research into mRNA vaccines. Research would have helped to protect people, not harm them. Another one is Trump's proposed tariff of 250% on pharmaceuticals produced in Australia and other countries. This would seem to be designed to make Americans pay more for needed medicines or to bully Australian producers. All it will achieve, if it actually happens, is to harm American citizens. Keep well, if you can afford to. Dennis Fitzgerald, Melbourne, Australia
Zawya
28-07-2025
- Zawya
Egypt, Novartis explore expanding collaboration in oncology, cardiology
Egypt - Ahmed El-Sobky, Chairperson of Egypt's General Authority for Healthcare and supervisor of the Universal Health Insurance Project, met on Sunday with Gehan El-Emary, Chairperson and Managing Director of Novartis Egypt, to follow up on the progress of a memorandum of understanding (MoU) signed in February. The MoU, which aims to enhance cancer care, broaden cardiology collaboration, and promote medical training, has seen significant developments, according to an official statement from the Authority. El-Sobky highlighted the authority's goal to transform the Aswan Oncology Center into a leading regional and research hub for cancer treatment, with the involvement of international partners, including Novartis. During the meeting, El-Sobky extended a formal invitation to Novartis officials to visit the center and explore potential areas for further collaboration on-site. The meeting also focused on efforts to modernize clinical protocols for heart disease and breast cancer, alongside expanding training programs for healthcare providers in line with global best practices. El-Sobky emphasized the importance of increasing the number of physicians benefiting from these programs in partnership with Novartis to strengthen healthcare delivery across Egypt. In addition, the two sides discussed the possibility of launching a certified digital training platform designed to equip family doctors with the tools and skills necessary to manage non-communicable diseases such as hypertension, diabetes, and chronic heart conditions. They also explored innovative strategies to raise public health awareness and ensure continuity of care in underserved areas. Gehan El-Emary expressed pride in the growing partnership between Novartis and the General Authority for Healthcare, noting the tangible successes achieved through their joint initiatives. She reaffirmed Novartis's ongoing commitment to expanding its collaboration with the Authority, particularly in the areas of early detection, cancer care, cardiology, and chronic disease management.
